| Literature DB >> 31009559 |
Makoto Fushimi1, Ikuo Fujimori1, Takeshi Wakabayashi1, Tomoaki Hasui1, Youichi Kawakita1, Keisuke Imamura1, Tomoko Kato1, Morio Murakami1, Tsuyoshi Ishii1, Yorifumi Kikko1, Maki Kasahara1, Atsushi Nakatani1, Yuto Hiura1, Maki Miyamoto1, Kumar Saikatendu2, Hua Zou2, Scott Weston Lane2, J David Lawson2, Hiroshi Imoto1.
Abstract
Anaplastic lymphoma kinase (ALK), a member of the receptor tyrosine kinase family, is predominantly expressed in the brain and implicated in neuronal development and cognition. However, the detailed function of ALK in the central nervous system (CNS) is still unclear. To elucidate the role of ALK in the CNS, it was necessary to discover a potent, selective, and brain-penetrant ALK inhibitor. Scaffold hopping and lead optimization of N-(2,4-difluorobenzyl)-3-(1 H-pyrazol-5-yl)imidazo[1,2- b]pyridazin-6-amine 1 guided by a cocrystal structure of compound 1 bound to ALK resulted in the identification of (6-(1-(5-fluoropyridin-2-yl)ethoxy)-1-(5-methyl-1 H-pyrazol-3-yl)-1 H-pyrrolo[2,3- b]pyridin-3-yl)((2 S)-2-methylmorpholin-4-yl)methanone 13 as a highly potent, selective, and brain-penetrable compound. Intraperitoneal administration of compound 13 significantly decreased the phosphorylated-ALK (p-ALK) levels in the hippocampus and prefrontal cortex in the mouse brain. These results suggest that compound 13 could serve as a useful chemical probe to elucidate the mechanism of ALK-mediated brain functions and the therapeutic potential of ALK inhibition.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31009559 DOI: 10.1021/acs.jmedchem.8b01630
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446